BCAT2 and bladder transitional cell carcinoma: In addition, the development of new targets, such as BCAT2, EMT-related signature and S100A5 (Xiao et al., 2022; Cai et al., 2023; Li et al., 2023), was playing an increasingly important role in immunotherapy for BLCA.